Detail akcie Travere Therapet Rg online

Business Summary: Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Travere Therapeutics Inc revenues increased from $158.4M to $361M. Net loss before extraordinary items decreased 89% to $28.3M. Revenues reflect FILSPARI segment increase from $82.6M to $218.7M. Lower net loss reflects In-process research and development decrease from $65.2M (expense) to $0K, Research and development - Balancing decrease of 6% to $135.3M (expense).